185 related articles for article (PubMed ID: 17508683)
1. [Benefits and risks of drug-eluting stents].
Zijlstra F
Ned Tijdschr Geneeskd; 2007 May; 151(18):1005-7. PubMed ID: 17508683
[TBL] [Abstract][Full Text] [Related]
2. Drug-eluting coronary stents: many meta-analyses, little benefit.
Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
[TBL] [Abstract][Full Text] [Related]
3. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
[TBL] [Abstract][Full Text] [Related]
4. Off-label use of stents: bare-metal versus drug-eluting stents.
Girod JP; Mulukutla SR; Marroquin OC
Expert Rev Cardiovasc Ther; 2008 Sep; 6(8):1095-106. PubMed ID: 18793112
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up.
Roukoz H; Bavry AA; Sarkees ML; Mood GR; Kumbhani DJ; Rabbat MG; Bhatt DL
Am J Med; 2009 Jun; 122(6):581.e1-10. PubMed ID: 19486720
[TBL] [Abstract][Full Text] [Related]
6. The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: insights from randomized clinical trials.
Kumbhani DJ; Bavry AA; Kamdar AR; Helton TJ; Bhatt DL
Am Heart J; 2008 Apr; 155(4):640-7. PubMed ID: 18371470
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
[TBL] [Abstract][Full Text] [Related]
8. The conundrum of late and very late stent thrombosis following drug-eluting stent implantation.
Garg P; Mauri L
Curr Opin Cardiol; 2007 Nov; 22(6):565-71. PubMed ID: 17921745
[TBL] [Abstract][Full Text] [Related]
9. Comparative safety and efficacy of a sirolimus-eluting versus paclitaxel-eluting stent: a meta-analysis.
Gurm HS; Boyden T; Welch KB
Am Heart J; 2008 Apr; 155(4):630-9. PubMed ID: 18371469
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.
Schömig A; Dibra A; Windecker S; Mehilli J; Suárez de Lezo J; Kaiser C; Park SJ; Goy JJ; Lee JH; Di Lorenzo E; Wu J; Jüni P; Pfisterer ME; Meier B; Kastrati A
J Am Coll Cardiol; 2007 Oct; 50(14):1373-80. PubMed ID: 17903638
[TBL] [Abstract][Full Text] [Related]
11. Drug-eluting compared with bare-metal coronary stents among elderly patients.
Groeneveld PW; Matta MA; Greenhut AP; Yang F
J Am Coll Cardiol; 2008 May; 51(21):2017-24. PubMed ID: 18498954
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial.
Kelbaek H; Kløvgaard L; Helqvist S; Lassen JF; Krusell LR; Engstrøm T; Bøtker HE; Jørgensen E; Saunamäki K; Aljabbari S; Thayssen P; Galløe A; Jensen GV; Thuesen L
J Am Coll Cardiol; 2008 May; 51(21):2011-6. PubMed ID: 18498953
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials.
Kirtane AJ; Ellis SG; Dawkins KD; Colombo A; Grube E; Popma JJ; Fahy M; Leon MB; Moses JW; Mehran R; Stone GW
J Am Coll Cardiol; 2008 Feb; 51(7):708-15. PubMed ID: 18279734
[TBL] [Abstract][Full Text] [Related]
14. From randomized trials to routine clinical practice: an evidence-based approach for the use of drug-eluting stents.
Thanigaraj S; Wollmuth JR; Zajarias A; Chemmalakuzhy J; Lasala JM
Coron Artery Dis; 2006 Dec; 17(8):673-9. PubMed ID: 17119375
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of drug-eluting stents: on-label and off-label perspectives.
Weisz G; Stone GW
Rev Cardiovasc Med; 2008; 9(1):46-61. PubMed ID: 18418309
[TBL] [Abstract][Full Text] [Related]
16. [Drug-eluting stents for diabetic patients. A critical appraisal of the currently available data from randomized trials].
Silber S; Herdeg C
Herz; 2008 Apr; 33(3):196-205. PubMed ID: 18568314
[TBL] [Abstract][Full Text] [Related]
17. Comparison of drug-eluting stents and coronary artery bypass surgery for the treatment of multivessel coronary disease: three-year follow-up results from a single institution.
Li Y; Zheng Z; Xu B; Zhang S; Li W; Gao R; Hu S
Circulation; 2009 Apr; 119(15):2040-50. PubMed ID: 19349321
[TBL] [Abstract][Full Text] [Related]
18. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation.
Stone GW; Ellis SG; Colombo A; Dawkins KD; Grube E; Cutlip DE; Friedman M; Baim DS; Koglin J
Circulation; 2007 Jun; 115(22):2842-7. PubMed ID: 17515458
[TBL] [Abstract][Full Text] [Related]
19. The pathophysiology and burden of restenosis.
Weintraub WS
Am J Cardiol; 2007 Sep; 100(5A):3K-9K. PubMed ID: 17719351
[TBL] [Abstract][Full Text] [Related]
20. Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives.
Jaffe R; Strauss BH
J Am Coll Cardiol; 2007 Jul; 50(2):119-27. PubMed ID: 17616295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
